Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Stem Cells in ALS
NCT04849065Phase 2Unknown
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in amyotrophic lateral sclerosis (ALS), sponsored by Fundación para la Formación e Investigación Sanitaria. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04849065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849065.